Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 200 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 100 mg - injection, solution - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - oxaliplatin, quantity: 50 mg - injection, solution - excipient ingredients: lactose monohydrate; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; - treatment of advanced colorectal cancer

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - tetrabenazine, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose; maize starch; purified talc; magnesium stearate; iron oxide yellow; colloidal anhydrous silica; sodium starch glycollate type a - may be useful for the control of chorea, hemiballismus, tardive and buccolingual dyskinesias and certain dystonic syndromes.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 52.45 mg/ml (equivalent: cefaclor, qty 50 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; colloidal anhydrous silica; xanthan gum; sucrose; sodium benzoate; allura red ac; sodium citrate dihydrate; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - cefaclor monohydrate, quantity: 26.23 mg/ml (equivalent: cefaclor, qty 25 mg/ml) - oral liquid, powder for - excipient ingredients: citric acid; xanthan gum; sucrose; sodium citrate dihydrate; colloidal anhydrous silica; sodium benzoate; allura red ac; flavour; potable water; simethicone; cetostearyl alcohol - infections due to susceptible microorganisms. lower respiratory infections, including pneumonia, bronchitis and exacerbations of chronic bronchitis. upper respiratory tract infections, including pharyngitis and tonsillitis and otitis media. skin and skin structure infections. urinary tract infections, including pyelonephritis and cystitis. note: penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. cefaclor appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 128.497 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 32.124 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - sitagliptin fumarate, quantity: 64.249 mg - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; hydrogenated castor oil; glycerol dibehenate; magnesium stearate; titanium dioxide; hypromellose; purified talc; iron oxide yellow; macrogol 6000; iron oxide red - sitagliptin sun (sitagliptin fumarate) is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus as: - monotherapy when metformin is considered inappropriate due to intolerance; or - in combination with other anti-hyperglycaemic agents, including insulin,[see 5.1 pharmacodynamic properties, clinical trials, 4.5 interactions with other medicines and other forms of interactions for available data on different add-on combination therapies].

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - levothyroxine sodium, quantity: 0.1 mg - tablet - excipient ingredients: magnesium stearate; hyprolose; pregelatinised starch; microcrystalline cellulose; sunset yellow fcf aluminium lake; quinoline yellow aluminium lake - levothyroxine sodium is indicated for the management of demonstrated thyroid hormone deficiency.,levothyroxine sodium is also used to suppress thyrotropin (tsh) for the management of tsh-responsive tumours of the thyroid.